Study guide
Section 13.2: HBOT, Biophysical Agents & Advanced Biologics
ABWM Certified Wound Specialist CWS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the ABWM CWS Exam 1.2 How to Use This Study Guide & Blueprint Strategy
2 Chapter 2: Comprehensive Patient & Wound Assessment
2.1 Patient History & Systemic Risk Factors 2.2 Physical Examination & Anatomical Wound Classification 2.3 Quantitative Wound Measurement & Documentation 2.4 Bioburden & Infection Assessment
3 Chapter 3: Vascular Assessment & Diagnostic Testing
Section 3.1: Ankle-Brachial Index (ABI) & Toe-Brachial Index (TBI) Interpretation Section 3.2: Advanced Vascular Diagnostics Section 3.3: Neuropathic & Sensory Assessment
4 Chapter 4: Laboratory, Imaging & Diagnostic Approaches
Section 4.1: Laboratory Evaluation in Wound Care Section 4.2: Imaging Modalities for Wounds & Bone Section 4.3: Differential Diagnosis of Recalcitrant & Atypical Wounds
5 Chapter 5: Physiology of Wound Healing & Tissue Repair
5.1 Hemostasis & Inflammatory Phase Dynamics 5.2 Proliferative & Remodeling Phases 5.3 Growth Factors & Extracellular Matrix (ECM)
6 Chapter 6: Biofilm Biology & Wound Bed Preparation
6.1 Biofilm Pathophysiology & Management Strategies 6.2 TIME Framework & Wound Bed Preparation 6.3 Moisture Balance & Exudate Management
7 Chapter 7: Pressure Injuries & Moisture-Associated Skin Damage
7.1 Pressure Injury Pathophysiology & NPIAP Staging 7.2 Risk Assessment Tools & Support Surface Selection 7.3 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis
8 Chapter 8: Lower Extremity Ulcers (Venous, Arterial & Mixed)
Section 8.1: Venous Leg Ulcers & CEAP Classification Section 8.2: Arterial Ulcers & Peripheral Artery Disease Section 8.3: Mixed Venous-Arterial Ulcers & Lymphedema
9 Chapter 9: Diabetic Foot Ulcers & Neuropathic Wounds
Section 9.1: Diabetic Foot Ulcer Pathophysiology & Classification Section 9.2: Diabetic Foot Infection & Osteomyelitis Management
10 Chapter 10: Thermal Injuries, Surgical Wounds & Special Etiologies
Section 10.1: Burn Injuries & Thermal Damage Section 10.2: Surgical Wounds, Dehisced Incisions & Fistulas Section 10.3: Dermatological, Pediatric & Miscellaneous Wound Types
11 Chapter 11: Debridement & Topically Applied Therapies
Section 11.1: Debridement Modalities & Selection Section 11.2: Wound Dressing Selection & Categories Section 11.3: Topical Antimicrobial Agents & Antiseptics
12 Chapter 12: Compression Therapy & Advanced Off-Loading
Section 12.1: Compression Therapy Modalities & Science Section 12.2: Off-Loading Devices & Biomechanical Protection
13 Chapter 13: Advanced & Adjunctive Wound Therapies
Section 13.1: Negative Pressure Wound Therapy (NPWT) Section 13.2: HBOT, Biophysical Agents & Advanced Biologics Section 13.3: Systemic Nutrition, Hydration & Pain Management
14 Chapter 14: Professional Practice, Reimbursement & Interprofessional Care
14.1 Professional Ethics, Scope of Practice & ABWM Guidelines 14.2 Documentation, Coding & Reimbursement Standards 14.3 Interprofessional Team Roles & Quality Improvement
Section 13.2: HBOT, Biophysical Agents & Advanced Biologics
Key Takeaways Explain This Topic AI
HBOT increases dissolved plasma oxygen concentration by nearly 20-fold (from 0.3 to 6.0 mL/dL at 2.5 ATA) according to Henry's Law, supplying oxygen to hypoxic tissue independent of hemoglobin.
CMS-approved indications for HBOT include Wagner Grade 3+ Diabetic Foot Ulcers that failed 30 days of standard care, chronic refractory osteomyelitis, soft tissue radionecrosis, compromised flaps/grafts, and acute traumatic ischemia.
HBOT stimulates angiogenesis (VEGF release), enhances neutrophil oxidative killing (NADPH oxidase reactivation), suppresses clostridial alpha-toxin, and mobilizes bone marrow stem cells.
Cellular and Tissue-based Products (CTPs) include dehydrated human amnion/chorion membrane (dHACM), living bilayered constructs (Apligraf), single-layer dermal constructs (Dermagraft), and acellular dermal matrices (ADMs).
Electrical stimulation (commonly HVPC) and therapeutic ultrasound are ABWM Domain 3 biophysical technologies used as adjuncts when standard care stalls; they are not first-line replacements for etiology-directed care.
Last updated: July 2026
Section 13.2: Hyperbaric Oxygen Therapy (HBOT) & Advanced Biologics
When chronic wounds fail to progress through the normal phases of wound healing despite 30 days of optimal standard wound care (including debridement, moisture balance, infection control, and off-loading or compression), advanced adjunctive therapies are indicated. Among the most potent advanced modalities are Hyperbaric Oxygen Therapy (HBOT), Cellular and Tissue-based Products (CTPs / Skin Substitutes), and Autologous Blood-Derived Therapies such as Platelet-Rich Plasma (PRP). Mastery of the physiological principles, CMS coverage guidelines, structural properties, and application protocols of these therapies is essential for the ABWM Certified Wound Specialist (CWS).
Hyperbaric Oxygen Therapy (HBOT): Physiological Principles
Hyperbaric Oxygen Therapy involves the systemic administration of 100% medical-grade oxygen to a patient breathing inside a pressurized hyperbaric chamber (monoplace or multiplace) at ambient pressures greater than 1.0 Atmosphere Absolute (ATA), typically between 2.0 and 2.5 ATA .
Physical Laws & Dissolved Plasma Oxygen
Under normal atmospheric conditions (1.0 ATA at sea level), human arterial blood oxygen content is almost entirely determined by hemoglobin saturation (SaO2 ~98%), with a very small amount of dissolved oxygen in blood plasma (approximately 0.3 mL O2 per 100 mL of plasma or 0.3 vol%).
According to Henry's Law , the amount of gas dissolved in a liquid is directly proportional to the partial pressure of that gas above the liquid.
When a patient inhales 100% O2 at 2.0 to 2.5 ATA , arterial oxygen tension (PaO2) increases from normal levels of ~100 mmHg to over 1500–2000 mmHg .
This massive partial pressure gradient drives dissolved plasma oxygen concentrations up to 5.5 to 6.0 mL O2 per 100 mL of plasma (a 20-fold increase).
Crucially, this quantity of dissolved plasma oxygen is sufficient to meet total resting cellular metabolic demands without any contribution from hemoglobin . Consequently, oxygen can diffuse up to four times deeper into hypoxic, microvascularly compromised wound tissues where red blood cells cannot physically pass.
- Parameter Room Air (1.0 ATA) 100% O2 (1.0 ATA) 100% O2 (2.5 ATA)
- Inhaled FiO2 21% 100% 100%
- Arterial PaO2 ~100 mmHg ~600 mmHg ~1800–2000 mmHg
- Dissolved Plasma O2 0.3 mL / dL 1.8 mL / dL 6.0 mL / dL
- Hemoglobin Saturation 97–98% 100% 100%
- Tissue Oxygen Diffusion Baseline (64 µm) Increased 4x Baseline
- Cellular Mechanisms of HBOT
Hyperoxia-Induced Angiogenesis: HBOT creates steep oxygen gradients between normoxic vascularized tissue and the central hypoxic wound core. This oxygen gradient stimulates endothelial cells and macrophages to release Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), and basic fibroblast growth factor (bFGF), triggering neovascularization.
Enhancement of Leukocyte Bactericidal Function: Neutrophils require molecular oxygen to produce reactive oxygen species (ROS) via the NADPH oxidase system (the oxidative burst). Hypoxic wound beds (TcPO2 < 20 mmHg) paralyze neutrophil bacterial killing. HBOT restores tissue oxygen levels above 30–40 mmHg, reinstating neutrophil phagocytosis and killing of aerobic pathogens (especially Staphylococcus aureus and Pseudomonas aeruginosa ).
Suppression of Clostridial Toxins & Anaerobic Pathogens: High tissue oxygen tensions directly inhibit anaerobic bacterial replication and shut down alpha-toxin production in Clostridium perfringens (gas gangrene).
Fibroblast Proliferation & Collagen Synthesis: Prolyl and lysyl hydroxylase enzymes require molecular oxygen as a co-substrate to cross-link procollagen into mature triple-helix collagen fibers. HBOT provides necessary O2 for extracellular matrix building.
Stem Cell Mobilization: HBOT induces nitric oxide synthase activity in bone marrow, mobilizing autologous CD34+ vasculogenic stem cells into systemic circulation.
Approved CMS Indications & Clinical Protocols
The Centers for Medicare & Medicaid Services (CMS) strictly regulates reimbursement for HBOT. Candidates must meet specific diagnostic criteria and document failure of prior standard therapy.
CMS Approved Indication Clinical Criteria & Required Prerequisites Standard HBOT Treatment Protocol
Diabetic Foot Ulcers (DFU) - Wagner Grade 3+ Must be Wagner Grade 3 (deep ulcer with abscess, osteomyelitis, or joint capsule involvement) or higher AND failed 30 days of documented standard wound care (off-loading, debridement, infection control, moist dressing). 30 to 40 sessions (1.5–2 hours/day at 2.0–2.5 ATA, 5 days/week); re-evaluate at 30 days.
Chronic Refractory Osteomyelitis Bone infection persistent despite appropriate surgical debridement and culture-directed parenteral systemic antibiotics for 4 to 6 weeks. 30 to 40 sessions adjunctive to ongoing antibiotic/surgical therapy.
Soft Tissue Radionecrosis & Osteoradionecrosis Radiation-induced tissue damage (e.g., radiation cystitis, proctitis, head/neck osteoradionecrosis) presenting months to years after radiotherapy. 30 to 40 sessions pre-operatively; 10 sessions post-operatively for surgical procedures in irradiated tissue.
Compromised Skin Flaps and Grafts Acute ischemia or partial necrosis of a surgical skin flap or pedicle graft (not indicated for routine, healthy grafts). 10 to 20 sessions administered urgently (twice daily initially, then daily).
Crush Injury & Acute Traumatic Ischemia Acute traumatic tissue injury, compartment syndrome, or reattached limb with severe microvascular compromise. Urgent BID HBOT for 48–72 hours at 2.5 ATA.
Cellular and Tissue-Based Products (CTPs / Skin Substitutes)
Cellular and Tissue-based Products (CTPs), historically termed "skin substitutes," encompass a diverse spectrum of biologically derived matrices and living cellular constructs designed to replace, repair, or stimulate host extracellular matrix (ECM).
Classification & Biomaterial Sources
CTPs are categorized by their cellular composition, structural layering, and tissue origin:
Human Amniotic and Chorionic Membrane Derivatives (dHACM):
Structure: Dehydrated or cryopreserved human amnion/chorion tissue harvested from screened, elective post-cesarean placenta donors.
Composition: Retains native basement membrane, collagen types I, III, IV, V, fibronectin, laminin, and over 300 active growth factors and cytokines (PDGF, TGF-beta, VEGF, bFGF, TIMPs).
Mechanism: Provides a non-immunogenic structural scaffold while delivering sustained anti-inflammatory, anti-microbial, and pro-angiogenic signals to recalcitrant wound beds.
Bilayered Living Cell Constructs (e.g., Apligraf):
Structure: Composed of an upper epidermal layer formed by living human neonatal keratinocytes and a lower dermal layer composed of living human neonatal fibroblasts embedded in a bovine type I collagen matrix.
Mechanism: Acts as a "living drug delivery system." Living keratinocytes and fibroblasts actively respond to the wound environment by synthesizing and secreting balanced arrays of cytokines, matrix metalloproteinases, and growth factors. Indicated for DFUs and Venous Leg Ulcers (VLUs).
Single-Layer Living Dermal Constructs (e.g., Dermagraft):
Structure: Human neonatal fibroblasts cultured on a bioabsorbable polyglactin mesh scaffold.
Mechanism: Cryopreserved fibroblasts become metabolically active upon thawing and placement, depositing human collagen, fibronectin, and growth factors to rebuild damaged dermis in full-thickness DFUs.
Acellular Dermal Matrices (ADMs - Allografts & Xenografts):
Structure: Human cadaveric dermis (allograft) or porcine/bovine/fetal bovine dermis/peritoneum (xenograft) processed via decellularization to remove all cellular antigens while preserving the native 3D extracellular matrix architecture.
Mechanism: Serves as a durable dermal template for host cell infiltration, fibrovascular ingrowth, and re-epithelialization.
CTP Category Example Products Primary Mechanism Shelf Life / Storage
Amniotic/Chorionic Membrane (dHACM) Epifix, AmnioBand Growth factor signaling & ECM scaffold Ambient temp; 5-year shelf life
Bilayered Living Cell Construct Apligraf Living cytokine & ECM factory Room temp; 15-day shelf life
Single-Layer Living Dermal Construct Dermagraft Living dermal fibroblast matrix synthesis Cryopreserved (-80°C)
Acellular Dermal Matrix (ADM) AlloDerm, MatriStem, Oasis Structural ECM scaffold for host cell migration Ambient / Room temperature
Platelet-Rich Plasma (PRP) & Autologous Blood Products
Platelet-Rich Plasma (PRP) is an autologous biologic therapy prepared by centrifuging whole blood to concentrate platelets above baseline systemic concentrations (typically 3- to 7-fold baseline , or >1,000,000 platelets/µL).
Biological Cascade & Growth Factor Release
Upon activation with thrombin, calcium chloride, or collagen, concentrated platelets undergo degranulation, releasing stored pre-formed growth factors from their alpha-granules :
Platelet-Derived Growth Factor (PDGF): Potent chemoattractant for neutrophils, macrophages, and fibroblasts; stimulates angiogenesis and fibrogenesis.
Transforming Growth Factor-Beta (TGF-beta): Stimulates extracellular matrix synthesis and collagen production.
Vascular Endothelial Growth Factor (VEGF): Promotes microvascular endothelial cell proliferation and tubulogenesis.
Epidermal Growth Factor (EGF): Accelerates keratinocyte migration and re-epithelialization.
Clinical Application Protocol
PRP can be formulated as a liquid for injection into chronic wound margins or combined with thrombin/calcium to form a PRP gel matrix that is applied directly to the wound bed. It is particularly valuable for recalcitrant neuropathic foot ulcers and chronic non-healing surgical wounds where autologous signaling is severely blunted.
Clinical Case Vignette
Clinical Scenario: A 62-year-old male with a 12-year history of poorly controlled type 2 diabetes presents with a non-healing plantar ulcer over the head of the first metatarsal measuring 2.5 cm × 2.0 cm × 0.8 cm. Probe-to-bone testing is positive, and MRI confirms osteomyelitis of the first metatarsal head. Vascular workup shows ABI 0.95. The patient completes surgical resection of the infected bone and 6 weeks of culture-directed IV vancomycin. However, at 30 days post-op, a clean, non-healing Grade 3 wound deficit remains without evidence of active infection.
Clinical Analysis: The patient has a Wagner Grade 3 DFU that has failed 30 days of documented standard therapy following surgical resolution of osteomyelitis. Under CMS criteria, this patient meets the exact requirements for adjunctive Hyperbaric Oxygen Therapy (HBOT) (30–40 sessions at 2.0–2.5 ATA). Furthermore, once a clean, vascularized wound bed is achieved, applying a Cellular and Tissue-based Product (CTP) such as dHACM or Apligraf can accelerate definitive wound closure.
Biophysical Technologies: Electrical Stimulation & Therapeutic Ultrasound
ABWM Domain 3 (Patient Management) explicitly tests biophysical technologies , including electrical stimulation and ultrasound. These modalities are adjuncts for stalled chronic wounds after etiology, perfusion, infection, and off-loading have been addressed—not stand-alone cures.
Electrical Stimulation (E-Stim)
High-voltage pulsed current (HVPC) is the most commonly studied waveform in wound care. Proposed mechanisms include:
- Galvanotaxis (directional migration of neutrophils, macrophages, and fibroblasts along an electrical gradient)
- Increased local perfusion and angiogenesis signaling
- Reduced local edema and bacterial burden in some laboratory models
- Support for collagen deposition and epithelial migration when the wound edge is viable
Practical clinical framing for the exam:
Use as an adjunct for chronic pressure injuries, venous ulcers, or neuropathic ulcers that fail to progress despite optimized standard care.
Electrodes are typically placed to deliver current through or around the wound bed per protocol; polarity strategies may change as healing progresses (clinicians follow device/protocol guidance rather than memorizing brand-specific settings).
Contraindications / cautions: malignancy in the treatment field, untreated osteomyelitis, placement over the carotid sinus or through the heart/pacemaker pathway, active deep vein thrombosis in the treatment region, and pregnancy (abdominal/lumbar fields). Always follow facility policy and manufacturer labeling.
Therapeutic Ultrasound
Distinguish therapeutic ultrasound used as a healing adjunct from low-frequency ultrasound used primarily for debridement :
Contact therapeutic ultrasound (typically 1–3 MHz in rehab settings) delivers mechanical energy that may influence cell membrane signaling, local circulation, and scar remodeling when applied around chronic wounds as an adjunct.
Non-contact low-frequency ultrasound (NCLFUS) and ultrasonic debridement devices use saline mist or probe energy to disrupt biofilm/slough and cleanse the bed; on the blueprint these often sit at the intersection of biophysical therapy and wound bed preparation.
Avoid treating over reproductive organs, eyes, CNS tissue, or sites of known malignancy; use caution over epiphyseal plates in children and over areas of acute untreated infection without a concurrent infection plan.
Exam Decision Rule
When a vignette describes a stalled but adequately perfused, off-loaded, and debrided wound, biophysical adjuncts (HVPC e-stim or therapeutic/NCLFUS ultrasound) are reasonable next-step options alongside —not instead of—compression, moisture balance, nutrition, and etiology control. Prefer revascularization, infection source control, or pressure relief first when those deficits are still present.